Akebia Therapeutics, Inc. (AKBA) Stock Price

AKBAStock

$0.67−77.05%52W

Market Cap$185.66M

P/E—

PEG Ratio—

Div yield—

Beta0.22

AKBA Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-66.96%

Price vs S&P 500 (4W)-27.28%

VGM Score39.34

P/CF (Annual)2.73x

Book Value / Share (Quarterly)$0.09

P/TBV (Annual)3.91x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-6.88%

Cash Flow / Share (Quarterly)$0.11

Price vs S&P 500 (YTD)-70.31%

Gross Margin (TTM)81.52%

Net Profit Margin (TTM)-13.54%

EPS (TTM)$-0.11

10-Day Avg Trading Volume8.18M

EPS Excl Extra (TTM)$-0.11

Revenue Growth (5Y)-4.32%

EPS (Annual)$-0.02

ROI (Annual)-2.36%

Gross Margin (Annual)82.91%

Net Profit Margin (5Y Avg)-47.54%

Cash / Share (Quarterly)$0.57

Revenue Growth QoQ (YoY)-21.36%

ROA (Last FY)-1.42%

Revenue Growth TTM (YoY)7.52%

EBITD / Share (TTM)$-0.05

ROE (5Y Avg)-487.05%

Operating Margin (TTM)-6.90%

Cash Flow / Share (Annual)$0.23

P/B Ratio7.42x

P/B Ratio (Quarterly)12.22x

Net Income / Employee (Annual)$-27,600

EV / Revenue (TTM)1.02x

Net Interest Coverage (TTM)0.85x

ROA (TTM)-8.17%

EV / EBITDA (TTM)39.60x

EPS Incl Extra (Annual)$-0.02

Current Ratio (Annual)1.55x

Quick Ratio (Quarterly)1.31x

3-Month Avg Trading Volume6.52M

52-Week Price Return-77.05%

EV / Free Cash Flow (Annual)3.71x

Revenue / Employee (TTM)$1,129,200

Tangible BV / Share (Quarterly)$0.12

P/S Ratio (Annual)0.79x

Asset Turnover (Annual)0.63x

52-Week High$3.20

Operating Margin (5Y Avg)-39.76%

EPS Excl Extra (Annual)$-0.02

CapEx CAGR (5Y)90.83%

26-Week Price Return-57.05%

Quick Ratio (Annual)1.42x

13-Week Price Return-50.00%

Total Debt / Equity (Annual)5.94x

Current Ratio (Quarterly)1.43x

Enterprise Value$222.45M

Revenue / Share Growth (5Y)-15.46%

Asset Turnover (TTM)0.60x

Book Value / Share Growth (5Y)-53.14%

Revenue / Employee (Annual)$1,217,500

Inventory Turnover (Annual)2.53x

Pretax Margin (Annual)-1.58%

Cash / Share (Annual)$0.70

3-Month Return Std Dev76.74%

Gross Margin (5Y Avg)77.94%

Net Income / Employee (TTM)$-152,900

ROE (Last FY)-16.39%

Net Interest Coverage (Annual)-0.61x

EPS Basic Excl Extra (Annual)$-0.02

P/FCF (TTM)2.53x

Receivables Turnover (TTM)3.47x

EV / Free Cash Flow (TTM)7.55x

Total Debt / Equity (Quarterly)7.69x

EPS Incl Extra (TTM)$-0.11

Receivables Turnover (Annual)5.80x

ROI (TTM)-13.21%

P/S Ratio (TTM)0.85x

Pretax Margin (5Y Avg)-47.40%

Revenue / Share (Annual)$0.92

Tangible BV / Share (Annual)$0.70

Forward P/E380.50x

Price vs S&P 500 (52W)-92.59%

Year-to-Date Return-58.39%

5-Day Price Return-15.21%

EPS Normalized (Annual)$-0.02

ROA (5Y Avg)-26.82%

Net Profit Margin (Annual)-2.26%

Month-to-Date Return-27.17%

Cash Flow / Share (TTM)$-0.13

EBITD / Share (Annual)$0.09

Operating Margin (Annual)9.95%

LT Debt / Equity (Annual)5.40x

P/CF (TTM)4.47x

ROI (5Y Avg)-94.04%

LT Debt / Equity (Quarterly)6.27x

EPS Basic Excl Extra (TTM)$-0.11

P/TBV (Quarterly)25.01x

P/B Ratio (Annual)13.10x

Inventory Turnover (TTM)2.72x

Pretax Margin (TTM)-12.71%

Book Value / Share (Annual)$0.12

Price vs S&P 500 (13W)-52.69%

Beta0.22x

P/FCF (Annual)3.10x

Revenue / Share (TTM)$0.81

ROE (TTM)-93.74%

52-Week Low$0.67

vGradeB

gGradeD

mGradeF

vgmGradeD

AKBA Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 5, 2026	-$0.03	-$0.03	-3.20%(-$0.00)
Q1 2026	May 7, 2026	-$0.02	-$0.03	-50.00%(-$0.01)
Q4 2025	Feb 26, 2026	-$0.06	-$0.05	+16.67%(+$0.01)
Q3 2025	Nov 10, 2025	-$0.01	$0.00	+100.00%(+$0.01)
Q2 2025	Aug 7, 2025	-$0.03	$0.03	+206.80%(+$0.05)

AKBA Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.36

4.18

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
AKBAAkebia Therapeutics, Inc.	B	D	F	0.8x	7.5%	81.5%	—	$0.67
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Akebia Therapeutics, Inc.

Akebia Therapeutics is a biopharmaceutical company specializing in chronic kidney disease treatments. Its marketed products include Auryxia for serum phosphorus control and iron deficiency anemia in CKD patients in the US, and Vafseo for CKD-related anemia in Japan. The company is advancing HIF-PH inhibitors in preclinical development.

AKBA Next Earnings Report

Report dateNov 9, 2026

QuarterQ3 2026

Report timeAMC

EPS estimate-$0.03

Revenue estimate$46.94M

Also reporting on Nov 9, 2026

Scheduled date with consensus estimates — both can change before the company reports.

Earnings calendar for November 2026

Companies in Related Industries

FATEFate Therapeutics, Inc.Biological Products
PLXProtalix BioTherapeutics, Inc. Common StockBiological Products
ALECAlector, Inc. Common StockBiological Products
NAGENiagen Bioscience, Inc. Common StockPharmaceutical Preparations
CGENCompugen LtdBiological Products
LTBRLightbridge Corp.Industrial Chemicals
IVVDInvivyd, Inc. Common StockBiological Products
STROSutro Biopharma, Inc.Biological Products

Same SIC sector, outside this company's own industry.

Analyst Sentiment

4.2

Buy

Consensus rating

52-Week Range

Low$0.67

High$3.20